Experts describe how the tumor microenvironment modulates clinical responses and how patient-derived ex vivo and engineered in vitro models can be used for pre-clinical immuno-oncology testing.
Dr. Nataliia Beztsinna and Dr. Marten Hornsveld describe the role of tumor microenvironment (TME) compartments in clinical responses, as well as ex vivo patient-derived tissue technologies capable of maintaining the native TME for pre-clinical testing. Complex in vitro models with the use of human stromal and immune co-cultures are discussed, together with the advantages of HCI to quantify intact tumor biology.
Key Topics Include:
- Examine the key components of the TME that affect immunotherapy responses. Discuss the main approaches to analyse the TME composition and the differences between ‘hot’ and ‘cold’ solid tumors
- Identify ex vivo assays capable of maintaining native human TME. Discuss the advantages of high content imaging assay on fresh patient tissue in 3D for deciphering complex immuno-oncology drug responses
- Comparison between in vitro based assays containing native TME or reconstituted TME
- How myeloid cells in the TME affect tumors and methods to study and target this compartment
- Advances in modelling the mesenchymal TME compartment in vitro and constructing pre-clinical mini-tumor platforms
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Resources
Presenters
Associate Director / Head of 3D Ex vivo Patient Tissue Platform
Crown Bioscience
Dr. Nataliia Beztsinna has a MS degree in Biochemistry and PhD in Biology-Chemistry interface. She is experienced in confocal microscopy, high content imaging, 3D cell culture, organoids, molecular imaging, primary patient tissue cultures, in vitro and in vivo cancer models and tumor- targeted drug delivery nanosystems. Currently Nataliia is working as a Head of 3D Ex Vivo Patient Tissue (EVPT) Platform. Her responsibilties include managing a small team of highly-skilled scientists, ensuring high quality execution of customer projects, interactions, technical advising and quote design for potential customers as well as research and development activities dedicated to the growth of the EVPT Platform.
Senior Scientist, Oncology
Crown Bioscience
Dr. Marten Hornsveld is a molecular biologist that focuses on understanding and targeting molecular signal transduction in cancer. During his PhD program, he studied the role of PI3K-AKT signaling in breast cancer using a variety of mouse and cell based models. In his postdoctoral research he moved into the organoid technology field and worked on building representative organoid models for pancreatic cancer. This resulted in the establishment of a novel close-to-patient mini-tumor model that can be employed for both basic research and pre-clinical studies. A year ago, he switched gears and started as a senior scientist at Crown Bioscience. Here, he continues to work on building pre-clinical tumor models to facilitate rapid discovery of promising lead compounds in the oncology field.
Production Partner
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical, and translational platforms to advance oncology and immuno-oncology.
Additional Content From Crown Bioscience
What’s Next in Preclinical Cancer Immunotherapy Research?
This webinar will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions.
Targeting T Cells Within the Cancer Immunity Cycle
In this webinar, speakers will discuss the role of T cell biology in cancer immunotherapy.
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
Experts provide an overview of ex vivo and in vitro methods, techniques, and model systems for research within the cancer-immunity cycle framework.
Additional Content From Scientist.com
Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials
Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Discover the Freshness of Frozen PBMCs – An Assessment of Cryopreservation Impact on T Cell Activation and Phenotype
Discover the impact of cryopreservation of PBMCs on T cell activation and phenotype in Lonza’s free webinar.
Related Content
The Translational Utility of Ultrasound and Photoacoustics in Head and Neck Oncology
Dr. Mukund Seshadri presents his interdisciplinary research on developing and evaluating ultrasound and photoacoustic imaging for oral oncology applications, with a focus on the prognostic utility of these methods in assessing treatment responses in head and neck cancer patients.
Assessing Antigen-Specific T-Cell Functionality with Dendritic Cell/CD8⁺ T Cell Co-culture
In this webinar, learn how to set up DC and CD8⁺ T cell co-culture experiments and assess T cell proliferation and killing activity.
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cancer Immunotherapy
In this webinar, Aditya Pratapa and Lorcan Sherry present a new workflow for analyzing multiplex immunoflurescence images.